-
Evidence-based updates in primary care medicine By Louis Kuritzky, MD
-
Multiple prospective, randomized trials have shown a mortality reduction in patients with reduced left ventricular ejection fraction who undergo prophylactic implantable cardioverter-defibrillator (ICD) therapy.
-
Primary percutaneous coronary intervention (PCI) is the optimal treatment for patients suffering ST-elevation myocardial infarction (STEMI).
-
Medications for Risk Reduction of Breast Cancer in Women
-
In clinical practice, patients with atrial fibrillation (AF) duration < 48 hours often undergo cardioversion without systemic anticoagulation.
-
Dabigatran is a novel anticoagulant that has been shown to be at least as good as warfarin at preventing thromboembolism in atrial fibrillation (AF).
-
Pacemaker or defibrillator leads have been shown to have attached thrombi in up to one-third of cases and asymptomatic pulmonary emboli have been documented in up to 20% of patients.
-
Most physicians who travel will encounter one or more emergencies during air travel. This paper reviews the experience of a medical communication center that serves five domestic and international airlines over a 34-month period.
-
Statin therapy has multiple beneficial effects on coronary plaque, including prevention of plaque progression and reduction in thrombotic events. It is not clear if the beneficial effect on clinical events is due to reduction in lipid content of plaque.
-
N-3 polyunsaturated fatty acids (n-3 FA) from fish have been reputed to prevent the development of cardiovascular disease (CVD) and have demonstrated some benefits in secondary prevention studies. Thus, this community-based investigator group in Italy conducted a double-blind, placebo-controlled trial of subjects with multiple risk factors for CVD (at least four, or one if diabetic) or evidence of atherosclerotic vascular disease, but without myocardial infarction (MI).